Geode Capital Management LLC grew its holdings in shares of Integer Holdings Co. (NYSE:ITGR - Free Report) by 1.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 764,528 shares of the medical equipment provider's stock after acquiring an additional 9,421 shares during the period. Geode Capital Management LLC owned about 2.28% of Integer worth $99,408,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. Contravisory Investment Management Inc. lifted its holdings in Integer by 55.9% during the 3rd quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider's stock worth $29,000 after buying an additional 80 shares during the period. Huntington National Bank lifted its stake in shares of Integer by 8,933.3% in the third quarter. Huntington National Bank now owns 271 shares of the medical equipment provider's stock worth $35,000 after acquiring an additional 268 shares during the period. Quest Partners LLC boosted its holdings in Integer by 3,688.9% in the second quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider's stock valued at $39,000 after acquiring an additional 332 shares during the last quarter. GAMMA Investing LLC increased its position in Integer by 74.1% during the 3rd quarter. GAMMA Investing LLC now owns 653 shares of the medical equipment provider's stock valued at $85,000 after purchasing an additional 278 shares during the period. Finally, Innealta Capital LLC bought a new position in Integer during the 2nd quarter worth approximately $110,000. Institutional investors and hedge funds own 99.29% of the company's stock.
A number of equities research analysts have recently commented on ITGR shares. Piper Sandler reaffirmed an "overweight" rating and issued a $140.00 price objective (up from $125.00) on shares of Integer in a research note on Friday, October 25th. KeyCorp increased their price target on Integer from $139.00 to $144.00 and gave the stock an "overweight" rating in a report on Tuesday, October 15th. Citigroup boosted their price objective on Integer from $130.00 to $145.00 and gave the company a "neutral" rating in a research note on Wednesday, December 11th. Benchmark raised their target price on Integer from $130.00 to $140.00 and gave the stock a "buy" rating in a research note on Monday, October 21st. Finally, Wells Fargo & Company reissued an "overweight" rating and issued a $160.00 price target on shares of Integer in a research note on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $145.44.
View Our Latest Research Report on ITGR
NYSE ITGR opened at $131.50 on Thursday. Integer Holdings Co. has a 52 week low of $94.56 and a 52 week high of $142.76. The business has a 50 day moving average price of $134.15 and a 200-day moving average price of $126.05. The company has a quick ratio of 2.09, a current ratio of 3.28 and a debt-to-equity ratio of 0.67. The company has a market cap of $4.41 billion, a price-to-earnings ratio of 40.59, a P/E/G ratio of 2.02 and a beta of 1.12.
Integer (NYSE:ITGR - Get Free Report) last announced its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 EPS for the quarter, beating analysts' consensus estimates of $1.36 by $0.07. Integer had a net margin of 6.70% and a return on equity of 11.63%. The business had revenue of $431.42 million during the quarter, compared to analyst estimates of $440.59 million. During the same quarter in the previous year, the business posted $1.27 EPS. Integer's quarterly revenue was up 8.7% on a year-over-year basis. As a group, equities analysts expect that Integer Holdings Co. will post 5.33 earnings per share for the current fiscal year.
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Integer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integer wasn't on the list.
While Integer currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.